Abstract: The disclosure generally relates to methods, cells, and compositions for preparing cardiac extracellular matrix. In particular, provided herein are methods for preparing a cardiac extracellular matrix using SUSD2 High fibroblasts and SUSD2 High myofibroblasts.

Abstract: A monitoring device mounted to a user can be used to estimate a position or orientation of a body portion of the user, such as a joint or jointed portion of the user. Radiation can be emitted toward the body portion and a reflection of this radiation can be received. The reflected radiation can then be used to estimate a position of the body portion of the user.

Abstract: A monitoring device mounted to a user can be used to estimate a position or orientation of a body portion of the user, such as a joint or jointed portion of the user. Radiation can be emitted toward the body portion and a reflection of this radiation can be received. The reflected radiation can then be used to estimate a position of the body portion of the user.

Abstract: Apparatus, methods, media and code for a product development tool. The tool may control a processor. The processor may be configured to determine that a first set of performance metrics does not satisfy a threshold analysis criterion. The performance metrics may correspond to a deployed product and a user segment. A user segment may be a set of individuals that use a product or service. The segment may be a sample of a population of users. An institution may provide the product to one or more of the customers to provide the customer with an opportunity to acquire or use additional measures of goods that the customer already has or uses.

Abstract: Disclosed are biomarkers, the expression of which is differentially regulated in subjects with multiple sclerosis (MS) as compared to subjects that do not have MS. Also described are methods of identification of such biomarkers, and methods of using such biomarkers as targets for the development and identification of therapeutic compounds and strategies for the treatment of MS, as well as methods and kits for the diagnosis of MS.

Abstract: Relative quantitative information about components of chemical or biological samples can be obtained from mass spectra by normalizing the spectra to yield peak intensity values that accurately reflect concentrations of the responsible species. A normalization factor is computed from peak intensities of those inherent components whose concentration remains constant across a series of samples. Relative concentrations of a component occurring in different samples can be estimated from the normalized peak intensities. Unlike conventional methods, internal standards or additional reagents are not required. The methods are particularly useful for differential phenotyping in proteomics and metabolomics research, in which molecules varying in concentration across samples are identified. These identified species may serve as biological markers for disease or response to therapy.